Tenofovir Alafenamide Tablets (trade name: Vemlidy), known as the “strongest HBV drug in history”, has been recommended by the latest European Association for the Study of the Liver (EASL) guidelines and American Association for the Study of Liver Diseases (AASLD) guidelines as a first-line therapy for the previously untreated chronic hepatitis B (CHB). With this, there are three first-line nucleoside/nucleotide analogs available clinically for treating CHB in China: tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), and entecavir (ETV), which have significant antiviral effects, however, what are their influences on the long-term outcome of treating hepatitis B patients?
